Shares of Merck & Co MRK decreased 3.4% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were down 6.67% over the past year to $1.40, which missed the estimate of $1.63.
Revenue of $12,080,000,000 up by 0.19% from the same period last year, which missed the estimate of $12,660,000,000.
Looking Ahead
Merck reaffirmed FY21 guidance.
Conference Call Details
Date: Apr 29, 2021
Time: 08:00 AM
ET Webcast URL: https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=8E92AEF0-C0A2-4C15-86B8-C351526F195A&LangLocaleID=1033&Referrer=https%3A%2F%2Fwww.merck.com%2F
Technicals
52-week high: $87.80
Company's 52-week low was at $71.72
Price action over last quarter: down 1.72%
Company Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
